文献速递类风湿关节炎

早期类风湿关节炎循环细胞外囊泡的microRNA含量作为生物标志物及甲氨蝶呤疗效介质

Micro-RNA content of circulating extracellular vesicles in early rheumatoid arthritis as biomarkers and mediators of methotrexate efficacy.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

本研究对46例未治疗早期RA、23例未治疗风湿性多肌痛(PMR)和12例排除显著炎症疾病者(NIC)的血清细胞外囊泡(EV)中798个microRNA进行谱分析,并在RA患者甲氨蝶呤(MTX)治疗6个月后重复检测。结果显示28个EV microRNA在早期RA(而非PMR)与NIC间稳健差异表达,基线EV microRNA特征对6个月MTX诱导缓解有预测潜力,13个microRNA在应答者与非应答者间的表达变化显著不同。

要点

  • 28个EV microRNA在早期RA(非PMR)与NIC间稳健差异表达,提示鉴别价值。
  • 基线EV microRNA特征经交叉验证偏最小二乘判别分析显示对6个月MTX诱导缓解有预测潜力。
  • 13个microRNA在MTX治疗中表达变化在应答者与非应答者间显著不同,其中4个在应答者中相对丰度增加。

核心结论

  • 血清EV microRNA有潜力作为诊断和治疗生物标志物,并提示MTX在早期RA中可能的新型治疗机制,需进一步研究。

研究设计与样本

  • 研究纳入46例未治疗RA、23例未治疗PMR(炎症疾病对照组)和12例排除显著炎症疾病者(NIC),采用NanoString对血清EV中798个microRNA进行谱分析,RA患者MTX治疗6个月后重复检测,分析考虑多重检验校正。

主要发现

  • 校正年龄和性别后,28个EV microRNA在早期RA(而非PMR)与NIC间稳健差异表达。
  • 交叉验证偏最小二乘判别分析提示基线EV microRNA特征对6个月MTX诱导缓解有预测潜力。
  • 13个microRNA在MTX治疗过程中的表达变化在应答者与非应答者间显著不同。
  • 应答者中相对丰度增加的4个microRNA(miR-212-3p、miR-338-5p、miR-410-3p和miR-537)已知参与调控滑膜成纤维细胞的致病潜力。

关键数值与推荐

  • 798个microRNA从血清来源EV中分离并谱分析。
  • 28个EV microRNA在早期RA(而非PMR)与NIC间稳健差异表达。
  • 13个microRNA在MTX治疗中表达变化在应答者与非应答者间显著不同。
  • 4个在应答者中相对丰度增加的microRNA为miR-212-3p、miR-338-5p、miR-410-3p和miR-537。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出所提示的MTX在早期RA中的新型治疗机制需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Extracellular vesicles (EVs) are abundant in body fluids, contributing to intercellular signalling by transferring cargo that includes microRNAs (miRs)-themselves implicated in pathobiology. For the first time we evaluated the potential of EV miRs to contribute diagnostic information in early RA, predict methotrexate (MTX) efficacy or shed light on the drug's mechanism of action. METHODS: Seven hundred and ninety-eight miRs isolated from serum-derived EVs of 46 patients with untreated RA, 23 with untreated polymyalgia rheumatica (PMR; inflammatory disease control group) and 12 in whom significant inflammatory disease had been excluded (non-inflammatory controls; NICs) were profiled (NanoString); the same measurements were made for RA patients after 6 months' MTX treatment. Analyses took multiple testing into account. RESULTS: Twenty-eight EV miRs were robustly differentially expressed between early RA (but not PMR) patients and NICs after correction for age and sex, suggesting discriminatory value. Cross-validated partial least squares-discriminant analysis also indicated the predictive potential of a distinct baseline EV miR signature with respect to MTX-induced remission at 6 months. The change in expression of 13 miRs over the course of MTX treatment differed significantly between responders and non-responders, and four of those exhibiting increased relative abundance amongst responders have known roles in regulating the pathogenic potential of synovial fibroblasts, namely miR-212-3p, miR-338-5p, miR-410-3p and miR-537. CONCLUSION: Our data highlight the potential of serum EV miRs as diagnostic and therapeutic biomarkers, highlighting a novel potential mechanism by which MTX may exert its therapeutic effect in early RA that warrants further investigation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Maunder D, Brown PM, Barron-Millar B, et al. Micro-RNA content of circulating extracellular vesicles in early rheumatoid arthritis as biomarkers and mediators of methotrexate efficacy. Rheumatology (Oxford). 2024. PMID: 37930878. doi:10.1093/rheumatology/kead569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。